3-methyl salicylic acid: A long acting salicylate which decreases free fatty acid mobilisation and plasma cholesterol

A. N. Howard, D. E. Hyams, W. Everett, I. W. Jennings, G. A. Gresham, A. Bizzi, S. Garattini, E. Veneroni, T. A. Miettinen

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

A comparative study has been made of the action of 3-methyl salicylic acid, a derivative which has a much longer half-life than salicylic acid in man, on free fatty acid mobilisation and plasma cholesterol in the rat, rabbit, baboon and man. 3-Methyl salicylic acid decreased plasma free fatty acids in rats exposed to conditions of increased mobilisation, such as fasting, cold, and treatment with noradrenaline and ACTH. Evidence was obtained that a dose equivalent to salicylic acid given shortly before test was more effective. As for salicylate, 3-methyl salicylate decreased the in vitro production of FFA and glycerol liberated in vitro by the incubated rat epididymal fat pad. Administration of 3-methyl salicylic acid (100 mg/kg, body weight) reduced plasma cholesterol from 7 to 45% in baboons given an atherogenic, cholesterol-containing diet for one month. In acute experiments, the drug caused a marked choleresis in which the volume and excretion of bile acids but not cholesterol was increased. In the rabbit, the drug (100 mg/kg) caused a decrease in fasting FFA for up to four hours, followed by a large elevation. Inclusion of the drug in the diet of animals given a semi-synthetic diet of low cholesterol content did not reduce hypercholesterolaemia or the extent and severity of atherosclerotic lesions in the aorta. Administration of 0.9 g orally to fasting patients caused a 50% reduction in elevated plasma FFA after four hours and even after twelve hours the values were still subnormal. A double-blind control trial of nine hypercholesterolaemic and eight normal patients was conducted over twelve to eighteen months. Subjects in the hypercholesterolaemic group on chronic dosage (0.9-1.8 g per day) showed a fall of 25% in the mean plasma cholesterol, but there was no change in normal patients. Side effects, the chief of which were drowsiness and vomiting precluded the use of 3-methyl salicylate as a therapeutic agent in man.

Original languageEnglish
Pages (from-to)244-253
Number of pages10
JournalEuropean Journal of Pharmacology
Volume13
Issue number2
DOIs
Publication statusPublished - 1971

Fingerprint

Salicylic Acid
Salicylates
Nonesterified Fatty Acids
Cholesterol
Fasting
Papio
Pharmaceutical Preparations
Diet
Rabbits
Formulated Food
Sleep Stages
Hypercholesterolemia
Bile Acids and Salts
Adrenocorticotropic Hormone
Glycerol
Vomiting
Half-Life
Aorta
Adipose Tissue
Norepinephrine

Keywords

  • 3-Methyl salicylic acid
  • Atherosclerosis
  • Bile acids
  • Cholesterol
  • Fatty acids, free
  • o-Cresotinic acid
  • Plasma cholesterol

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Howard, A. N., Hyams, D. E., Everett, W., Jennings, I. W., Gresham, G. A., Bizzi, A., ... Miettinen, T. A. (1971). 3-methyl salicylic acid: A long acting salicylate which decreases free fatty acid mobilisation and plasma cholesterol. European Journal of Pharmacology, 13(2), 244-253. https://doi.org/10.1016/0014-2999(71)90156-7

3-methyl salicylic acid : A long acting salicylate which decreases free fatty acid mobilisation and plasma cholesterol. / Howard, A. N.; Hyams, D. E.; Everett, W.; Jennings, I. W.; Gresham, G. A.; Bizzi, A.; Garattini, S.; Veneroni, E.; Miettinen, T. A.

In: European Journal of Pharmacology, Vol. 13, No. 2, 1971, p. 244-253.

Research output: Contribution to journalArticle

Howard, AN, Hyams, DE, Everett, W, Jennings, IW, Gresham, GA, Bizzi, A, Garattini, S, Veneroni, E & Miettinen, TA 1971, '3-methyl salicylic acid: A long acting salicylate which decreases free fatty acid mobilisation and plasma cholesterol', European Journal of Pharmacology, vol. 13, no. 2, pp. 244-253. https://doi.org/10.1016/0014-2999(71)90156-7
Howard, A. N. ; Hyams, D. E. ; Everett, W. ; Jennings, I. W. ; Gresham, G. A. ; Bizzi, A. ; Garattini, S. ; Veneroni, E. ; Miettinen, T. A. / 3-methyl salicylic acid : A long acting salicylate which decreases free fatty acid mobilisation and plasma cholesterol. In: European Journal of Pharmacology. 1971 ; Vol. 13, No. 2. pp. 244-253.
@article{0ced11473bfc4ada854eddfed81cc387,
title = "3-methyl salicylic acid: A long acting salicylate which decreases free fatty acid mobilisation and plasma cholesterol",
abstract = "A comparative study has been made of the action of 3-methyl salicylic acid, a derivative which has a much longer half-life than salicylic acid in man, on free fatty acid mobilisation and plasma cholesterol in the rat, rabbit, baboon and man. 3-Methyl salicylic acid decreased plasma free fatty acids in rats exposed to conditions of increased mobilisation, such as fasting, cold, and treatment with noradrenaline and ACTH. Evidence was obtained that a dose equivalent to salicylic acid given shortly before test was more effective. As for salicylate, 3-methyl salicylate decreased the in vitro production of FFA and glycerol liberated in vitro by the incubated rat epididymal fat pad. Administration of 3-methyl salicylic acid (100 mg/kg, body weight) reduced plasma cholesterol from 7 to 45{\%} in baboons given an atherogenic, cholesterol-containing diet for one month. In acute experiments, the drug caused a marked choleresis in which the volume and excretion of bile acids but not cholesterol was increased. In the rabbit, the drug (100 mg/kg) caused a decrease in fasting FFA for up to four hours, followed by a large elevation. Inclusion of the drug in the diet of animals given a semi-synthetic diet of low cholesterol content did not reduce hypercholesterolaemia or the extent and severity of atherosclerotic lesions in the aorta. Administration of 0.9 g orally to fasting patients caused a 50{\%} reduction in elevated plasma FFA after four hours and even after twelve hours the values were still subnormal. A double-blind control trial of nine hypercholesterolaemic and eight normal patients was conducted over twelve to eighteen months. Subjects in the hypercholesterolaemic group on chronic dosage (0.9-1.8 g per day) showed a fall of 25{\%} in the mean plasma cholesterol, but there was no change in normal patients. Side effects, the chief of which were drowsiness and vomiting precluded the use of 3-methyl salicylate as a therapeutic agent in man.",
keywords = "3-Methyl salicylic acid, Atherosclerosis, Bile acids, Cholesterol, Fatty acids, free, o-Cresotinic acid, Plasma cholesterol",
author = "Howard, {A. N.} and Hyams, {D. E.} and W. Everett and Jennings, {I. W.} and Gresham, {G. A.} and A. Bizzi and S. Garattini and E. Veneroni and Miettinen, {T. A.}",
year = "1971",
doi = "10.1016/0014-2999(71)90156-7",
language = "English",
volume = "13",
pages = "244--253",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - 3-methyl salicylic acid

T2 - A long acting salicylate which decreases free fatty acid mobilisation and plasma cholesterol

AU - Howard, A. N.

AU - Hyams, D. E.

AU - Everett, W.

AU - Jennings, I. W.

AU - Gresham, G. A.

AU - Bizzi, A.

AU - Garattini, S.

AU - Veneroni, E.

AU - Miettinen, T. A.

PY - 1971

Y1 - 1971

N2 - A comparative study has been made of the action of 3-methyl salicylic acid, a derivative which has a much longer half-life than salicylic acid in man, on free fatty acid mobilisation and plasma cholesterol in the rat, rabbit, baboon and man. 3-Methyl salicylic acid decreased plasma free fatty acids in rats exposed to conditions of increased mobilisation, such as fasting, cold, and treatment with noradrenaline and ACTH. Evidence was obtained that a dose equivalent to salicylic acid given shortly before test was more effective. As for salicylate, 3-methyl salicylate decreased the in vitro production of FFA and glycerol liberated in vitro by the incubated rat epididymal fat pad. Administration of 3-methyl salicylic acid (100 mg/kg, body weight) reduced plasma cholesterol from 7 to 45% in baboons given an atherogenic, cholesterol-containing diet for one month. In acute experiments, the drug caused a marked choleresis in which the volume and excretion of bile acids but not cholesterol was increased. In the rabbit, the drug (100 mg/kg) caused a decrease in fasting FFA for up to four hours, followed by a large elevation. Inclusion of the drug in the diet of animals given a semi-synthetic diet of low cholesterol content did not reduce hypercholesterolaemia or the extent and severity of atherosclerotic lesions in the aorta. Administration of 0.9 g orally to fasting patients caused a 50% reduction in elevated plasma FFA after four hours and even after twelve hours the values were still subnormal. A double-blind control trial of nine hypercholesterolaemic and eight normal patients was conducted over twelve to eighteen months. Subjects in the hypercholesterolaemic group on chronic dosage (0.9-1.8 g per day) showed a fall of 25% in the mean plasma cholesterol, but there was no change in normal patients. Side effects, the chief of which were drowsiness and vomiting precluded the use of 3-methyl salicylate as a therapeutic agent in man.

AB - A comparative study has been made of the action of 3-methyl salicylic acid, a derivative which has a much longer half-life than salicylic acid in man, on free fatty acid mobilisation and plasma cholesterol in the rat, rabbit, baboon and man. 3-Methyl salicylic acid decreased plasma free fatty acids in rats exposed to conditions of increased mobilisation, such as fasting, cold, and treatment with noradrenaline and ACTH. Evidence was obtained that a dose equivalent to salicylic acid given shortly before test was more effective. As for salicylate, 3-methyl salicylate decreased the in vitro production of FFA and glycerol liberated in vitro by the incubated rat epididymal fat pad. Administration of 3-methyl salicylic acid (100 mg/kg, body weight) reduced plasma cholesterol from 7 to 45% in baboons given an atherogenic, cholesterol-containing diet for one month. In acute experiments, the drug caused a marked choleresis in which the volume and excretion of bile acids but not cholesterol was increased. In the rabbit, the drug (100 mg/kg) caused a decrease in fasting FFA for up to four hours, followed by a large elevation. Inclusion of the drug in the diet of animals given a semi-synthetic diet of low cholesterol content did not reduce hypercholesterolaemia or the extent and severity of atherosclerotic lesions in the aorta. Administration of 0.9 g orally to fasting patients caused a 50% reduction in elevated plasma FFA after four hours and even after twelve hours the values were still subnormal. A double-blind control trial of nine hypercholesterolaemic and eight normal patients was conducted over twelve to eighteen months. Subjects in the hypercholesterolaemic group on chronic dosage (0.9-1.8 g per day) showed a fall of 25% in the mean plasma cholesterol, but there was no change in normal patients. Side effects, the chief of which were drowsiness and vomiting precluded the use of 3-methyl salicylate as a therapeutic agent in man.

KW - 3-Methyl salicylic acid

KW - Atherosclerosis

KW - Bile acids

KW - Cholesterol

KW - Fatty acids, free

KW - o-Cresotinic acid

KW - Plasma cholesterol

UR - http://www.scopus.com/inward/record.url?scp=0014984503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0014984503&partnerID=8YFLogxK

U2 - 10.1016/0014-2999(71)90156-7

DO - 10.1016/0014-2999(71)90156-7

M3 - Article

C2 - 4322672

AN - SCOPUS:0014984503

VL - 13

SP - 244

EP - 253

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 2

ER -